{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:14:18Z","timestamp":1771017258807,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00277-017-3103-x","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T22:36:49Z","timestamp":1503441409000},"page":"1825-1832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Encouraging results with the compassionate use of hydralazine\/valproate (TRANSKRIP\u2122) as epigenetic treatment for myelodysplastic syndrome (MDS)"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5478-714X","authenticated-orcid":false,"given":"Myrna","family":"Candelaria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayra","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramiro","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Due\u00f1as-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,23]]},"reference":[{"key":"3103_CR1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"D Arber","year":"2016","unstructured":"Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Bau M et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"3103_CR2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079\u20132088","journal-title":"Blood"},{"key":"3103_CR3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.24102","volume":"90","author":"G Garcia Manero","year":"2015","unstructured":"Garcia Manero G (2015) Myelodysplastic syndromes: 2015 Update on diagnosis, risk stratification and management. Am J Hematol 90:831\u2013841","journal-title":"Am J Hematol"},{"key":"3103_CR4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","volume":"29","author":"G Garcia-Manero","year":"2011","unstructured":"Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29:516\u2013523","journal-title":"J Clin Oncol"},{"key":"3103_CR5","first-page":"605","volume":"28","author":"L Chen","year":"2010","unstructured":"Chen L, Kantarjian H, Guo Y et al (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605\u2013613","journal-title":"J Clin Oncol"},{"key":"3103_CR6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223\u2013232","journal-title":"Lancet Oncol"},{"key":"3103_CR7","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429\u20132440","journal-title":"J Clin Oncol"},{"key":"3103_CR8","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS et al (2006) Decitabine improves patient outcomes in myelodys-plastic syndromes: results of a phase III randomized study. Cancer 106:1794\u20131803","journal-title":"Cancer"},{"key":"3103_CR9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1517\/17425255.2014.947263","volume":"10","author":"A Due\u00f1as-Gonzalez","year":"2014","unstructured":"Due\u00f1as-Gonzalez A, Coronel J, Cetina L et al (2014) Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol 10:1433\u20131444","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3103_CR10","doi-asserted-by":"crossref","unstructured":"Bauman J, Shaheen M, Verschraegen CF, et. al (2014) A phase I protocol of hydralazine and valproic acid in advanced, previously treated solid cancers. Transl Oncol 7:349\u2013354","DOI":"10.1016\/j.tranon.2014.03.001"},{"key":"3103_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543784.2017.1291630","volume":"26","author":"JR Espinoza-Zamora","year":"2017","unstructured":"Espinoza-Zamora JR, Labardini-M\u00e9ndez J, Sosa-Espinoza A et al (2017) Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma: a phase II study. Expert Opin Investig Drugs 26:1\u20137","journal-title":"Expert Opin Investig Drugs"},{"key":"3103_CR12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-010-1090-2","volume":"90","author":"M Candelaria","year":"2011","unstructured":"Candelaria M, Herrera A, Labardini J et al (2011) Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol 90:379\u2013387","journal-title":"Ann Hematol"},{"key":"3103_CR13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1050-3862(98)00019-9","volume":"14","author":"KJ Livak","year":"1999","unstructured":"Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5\u2032 nuclease assay. Genet Anal 14:143\u2013149","journal-title":"Genet Anal"},{"key":"3103_CR14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/FPC.0b013e32834bec2b","volume":"21","author":"L Taja-Chayeb","year":"2011","unstructured":"Taja-Chayeb L, Gonz\u00e1lez-Fierro A, Miguez-Mu\u00f1oz C et al (2011) Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test. Pharmacogenet Genomics 21:894\u2013901","journal-title":"Pharmacogenet Genomics"},{"key":"3103_CR15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) criteria in myelodysplasia. Blood 108:419\u2013425","journal-title":"Blood"},{"key":"3103_CR16","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute. Division of Cancer Treatment & Diagnosis. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm (January 5th, 2017)"},{"key":"3103_CR17","first-page":"311","volume":"10","author":"S Shahrabi","year":"2016","unstructured":"Shahrabi S, Khosravi A, Shahjahani M, Rahim F, Saki N (2016) Genetics and epigenetics of myelodysplastic syndromes and response to drug therapy: new insights. Oncol Rev 10:311","journal-title":"Oncol Rev"},{"key":"3103_CR18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.12256","volume":"161","author":"YG Lee","year":"2013","unstructured":"Lee YG, Kim I, Yoon SS et al (2013) Korean Society of Haematology AML\/MDS working party. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol 161:339\u2013347","journal-title":"Br J Haematol"},{"key":"3103_CR19","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S et al (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302\u20132308","journal-title":"Blood"},{"key":"3103_CR20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/10428194.2014.914192","volume":"56","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Garcia-Manero G, Cornelison AM et al (2015) The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma 56:390\u2013394","journal-title":"Leuk Lymphoma"},{"key":"3103_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1295141","volume":"28","author":"JA Trubiano","year":"2017","unstructured":"Trubiano JA, Dickinson M, Thursky KA et al (2017) Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leuk Lymphoma 28:1\u20138. doi: https:\/\/doi.org\/10.1080\/10428194.2017.1295141","journal-title":"Leuk Lymphoma"},{"issue":"Suppl e","key":"3103_CR22","doi-asserted-by":"crossref","first-page":"iii57","DOI":"10.1093\/annonc\/mdu180","volume":"25","author":"P Fenaux","year":"2014","unstructured":"Fenaux P, Haase D, Sanz GF, Santini V, Buske C, ESMO Guidelines Working Group (2014) Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl e):iii57\u2013iii69","journal-title":"Ann Oncol"},{"key":"3103_CR23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.beha.2014.01.002","volume":"26","author":"P Fenaux","year":"2013","unstructured":"Fenaux P (2013) Myelodysplastic syndromes: state of the art pathology, diagnosis and management. Best Pract Res Clin Haematol 26:307\u2013308","journal-title":"Best Pract Res Clin Haematol"},{"key":"3103_CR24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1634\/theoncologist.2016-0211","volume":"22","author":"CR Cogle","year":"2017","unstructured":"Cogle CR, Kurtin SE, Bentley TG et al (2017) The incidence and health care resource burden of the myelodysplastic syndromes in patients in whom first-line hypomethylating agents fail. Oncologist 22:379\u2013385","journal-title":"Oncologist"},{"key":"3103_CR25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13148-011-0031-9","volume":"2","author":"A Kuendgen","year":"2011","unstructured":"Kuendgen A, Bug G, Ottmann OG et al (2011) Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacitidine and valproic acid. Clin Epigenetics 2:389\u2013399","journal-title":"Clin Epigenetics"},{"key":"3103_CR26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood.V112.11.945.945","volume":"112","author":"C Craddock","year":"2008","unstructured":"Craddock C, Goardon N, Griffiths M et al (2008) 5-azacitidine in combination with valproic acid induces complete remissions in patients with advanced acute myeloid leukaemia but does not eradicate clonal leukaemic stem\/progenitor cells. Blood 112:945","journal-title":"Blood"},{"key":"3103_CR27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.29085","volume":"121","author":"JP Issa","year":"2015","unstructured":"Issa JP, Garcia-Manero G, Huang X et al (2015) Results of phase II randomized study of low-dose decitabine with and without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 121:556\u2013561","journal-title":"Cancer"},{"key":"3103_CR28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.13832","volume":"172","author":"T Prebet","year":"2016","unstructured":"Prebet T, Sun Z, Ketterling RP et al (2016) Azacitidine with or without entinostat for the treatment of therapy-related myeloid neoplasms: further results of the E1905 North American Leukemia Intergroup Study. Br J Hematol 172:384\u2013391","journal-title":"Br J Hematol"},{"key":"3103_CR29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13059-014-0406-2","volume":"15","author":"K Lund","year":"2014","unstructured":"Lund K, Cole JJ, VanderKraats ND et al (2014) DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Genome Biol 15:406","journal-title":"Genome Biol"},{"key":"3103_CR30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.kint.2016.07.042","volume":"91","author":"B Tampe","year":"2017","unstructured":"Tampe B, Steinle U, Tampe D et al (2017) Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression. Kidney Int 91:157\u2013176","journal-title":"Kidney Int"},{"key":"3103_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ebiom.2014.11.005","volume":"2","author":"B Tampe","year":"2015","unstructured":"Tampe B, Tampe D, Zeisberg EM et al (2015) Induction of Tet3-dependent epigenetic remodeling by low-dose hydralazine attenuates progression of chronic kidney disease. EBioMedicine 2:19\u201336","journal-title":"EBioMedicine"},{"key":"3103_CR32","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood-2016-08-736587","volume":"129","author":"H Yan","year":"2017","unstructured":"Yan H, Wang Y, Qu X et al (2017) Distinct roles for TET family proteins in regulating human erythropoiesis. Blood 129:2002\u20132012","journal-title":"Blood"},{"key":"3103_CR33","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F, Dupont S, Valle VD et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289\u20132301","journal-title":"N Engl J Med"},{"key":"3103_CR34","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","volume":"116","author":"AE Smith","year":"2010","unstructured":"Smith AE, Mohamedali AM, Kulasekararaj A et al (2010) Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116:3923\u20133932","journal-title":"Blood"},{"key":"3103_CR35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029181","volume":"7","author":"M Candelaria","year":"2012","unstructured":"Candelaria M, de la Cruz-Hernandez E, Taja-Chayeb L et al (2012) DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. PLoS One 7:e29181","journal-title":"PLoS One"},{"key":"3103_CR36","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.febslet.2008.06.056","volume":"582","author":"D Spensberger","year":"2008","unstructured":"Spensberger D, Delwel R (2008) A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett 582:2761\u20132767","journal-title":"FEBS Lett"},{"key":"3103_CR37","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","volume":"278","author":"N Detich","year":"2003","unstructured":"Detich N, Bovenzi V, Szyf M (2003) Valproate induces replication-independent active DNA demethylation. J Biol Chem 278:27586\u201327592","journal-title":"J Biol Chem"},{"key":"3103_CR38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/carcin\/bgl167","volume":"28","author":"S Milutinovic","year":"2007","unstructured":"Milutinovic S, D'Alessio AC, Detich N, Szyf M (2007) Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 28:560\u2013571","journal-title":"Carcinogenesis"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3103-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T02:01:05Z","timestamp":1602813665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3103-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,23]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["3103"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3103-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,23]]}}}